☠️ The Graveyard of Longevity Biotechnology

Promise: SIRT1-activating resveratrol analogs to extend human lifespan — the sirtuin revolution.

Failure: Acquired by GSK for $720M in 2008 in a frenzy of anti-aging hype. Clinical trials failed — SRT501 caused kidney damage in myeloma patients. GSK shut down all Sirtris R&D by 2013. No longevity product ever reached market. The $720M became the most expensive lesson in aging biotech history.

Promise: Google/Alphabet's $2.5B+ anti-aging moonshot with AbbVie partnership. "Cure death" was the headline.

Failure: Over a decade and billions spent with zero approved drugs, near-total opacity, and no published longevity breakthroughs. Layoffs in 2024. Widely considered the most expensive stagnation in biotech history. The "cure for aging" promise remains unfulfilled.

Promise: Wnt pathway modulators to regenerate aging tissues — hair, skin, joints, cognition. Once valued at $12 billion.

Failure: Multiple Phase 2/3 failures in osteoarthritis (lorecivivint), hair loss, and tendon repair between 2021–2023. Valuation collapsed from $12B to near-nothing. Investor lawsuits. Rebranded as Biosplice and pivoted to cancer. The anti-aging regeneration thesis died.

Promise: Craig Venter's genome-sequencing + AI longevity health platform (Health Nucleus). Predict and prevent aging.

Failure: Burned through $300M+. Venter ousted in 2018. Multiple lawsuits. Massive layoffs. Never delivered longevity products. Pivoted to concierge health screening. The biggest name in genomics couldn't solve aging with sequencing alone.

Promise: Senolytic drugs to clear senescent "zombie" cells and reverse age-related diseases. The poster child of the senolytics movement.

Failure: UBX0101 failed Phase 2 for osteoarthritis in 2020 — no benefit over placebo. Stock collapsed 80-90%. Mass layoffs. Pivoted to narrow ophthalmology. The original thesis of systemic anti-aging senolytics in humans died with this trial.

Promise: TORC1 inhibitor RTB101 (rapalog) to boost immune function in the elderly and prevent age-related respiratory illness.

Failure: Phase 3 failed in 2019 — no reduction in respiratory infections. The most direct clinical test of the mTOR-aging hypothesis in humans failed. Company merged into Adicet Bio in 2020; longevity program killed entirely.

Promise: Telomerase activation/inhibition for aging reversal. One of the first companies to commercially pursue the telomere theory of aging.

Failure: Abandoned the entire anti-aging program in the 2000s. Pivoted completely to oncology (imetelstat). The original longevity thesis — that telomerase would reverse human aging — was never validated. A pioneer that walked away.

Promise: $3B partial epigenetic reprogramming for aging reversal. Backed by Jeff Bezos and Yuri Milner. Recruited top scientists globally.

Failure: Three+ years in: zero clinical programs, key scientists departing (2024), no published rejuvenation breakthroughs. The largest single investment in aging with nothing to show. While still technically alive, widely viewed as failing to deliver on its extraordinary promises despite unprecedented capital.

Promise: David Sinclair's umbrella company with 6 daughter companies covering all hallmarks of aging simultaneously.

Failure: Massive 2020-2021 restructuring killed all daughter companies (Senolytic Therapeutics, Spotlight, Continuum, Jumpstart, Iduna, Lua). The "address every hallmark" strategy collapsed. Narrowed to partial epigenetic reprogramming only. A cautionary tale of overambition in aging research.

Promise: Young plasma fractions (GRF6019, GRF6021) for aging reversal and neurodegeneration. Born from the "young blood" parabiosis research.

Failure: Phase 2 trials in Alzheimer's and Parkinson's failed 2020–2021. Acquired by Grifols, which shut down the aging R&D in 2022. The scientific paradigm of young blood fractions for human rejuvenation failed to translate clinically.

Promise: Jim Mellon's longevity holding company. Portfolio approach: metformin, NAD+, senolytics, AI — invest in everything aging.

Failure: Burned through $100M+. Several subsidiaries shut down (FoxBio, LyGenesis delays). Failed IPO attempts. Major write-downs 2023–2024. The "VC holding company" model for longevity proved unsustainable without clinical wins.

Promise: Young blood plasma transfusions for anti-aging at $8,000/liter. Direct-to-consumer "vampiric rejuvenation."

Failure: FDA issued a formal warning in February 2019 against all young-blood anti-aging claims. Shut down. Briefly restarted. Defunct. Became a symbol of unregulated anti-aging quackery that damaged the field's credibility.

Promise: Michael West's induced tissue regeneration (iTR) and PureStem for aging reversal via telomerase reprogramming.

Failure: Stock collapsed below $0.20. Delisted from NYSE in 2023. Zero revenue, zero clinical trials completed. Went bankrupt in 2024. A veteran aging researcher's final company dying without ever testing anything in humans.

Promise: AI-driven drug repurposing from human longevity biobank data. The most data-driven approach to geroscience drug discovery.

Failure: Lead program azelaprag halted after safety problems in Phase 2 (2024). The first major clinical geroscience program to reach advanced testing — and it failed. Stock collapsed. The poster child for AI-meets-aging drug discovery hit reality.

Promise: Sirtuin and insulin-signaling drugs for aging. Co-founded by Cynthia Kenyon and Lenny Guarente — two legends of aging biology.

Failure: Pivoted from anti-aging to diabetes. Ran out of funding. Effectively defunct by 2010–2012. Two Nobel-caliber scientists couldn't translate worm longevity genes into human drugs. The gap between model organisms and humans proved too wide.

Promise: Telomerase activators via small molecules to "cure aging itself." Screened 250,000+ compounds.

Failure: Could never translate a hit into a viable drug candidate. Ran out of funding by 2012. Downsized repeatedly. Essentially dormant. Decades of compound screening produced nothing clinically viable. Telomerase activation by small molecules remains unsolved.

Promise: Mitochondrial-targeted peptide elamipretide for age-related diseases — the energy-of-aging thesis.

Failure: Multiple Phase 3 failures: LHON failed, Barth syndrome rejected by FDA in 2020. Taken private at fire-sale prices in 2022. The mitochondrial peptide approach to aging disease failed in the clinic despite elegant preclinical biology.

Promise: NAD+ precursor supplement "Basis" (nicotinamide riboside + pterostilbene) to slow aging. Celebrity scientific advisors.

Failure: Sued by ChromaDex over IP. FDA warning letter for unapproved drug claims. Clinical trials failed to show meaningful aging reversal. Dropped "anti-aging" language. Downsized. A supplement company dressed up as longevity biotech.

Promise: Noah Davidsohn/George Church gene therapy combo for aging — first in dogs, then humans. Yamanaka factor cocktails.

Failure: Dog longevity program quietly shelved. Failed to produce human clinical data. Pivoted to rare genetic diseases. Layoffs 2023–2024. George Church's name couldn't compensate for the gap between gene therapy hype and aging biology reality.

Promise: Mitochondrial-derived peptides (MOTS-c, humanin analogs) for metabolic aging and age-related disease.

Failure: Multiple clinical failures. Could never translate the biology of mitochondrial peptides into a viable drug. Merged with Morphogenesis/TuHURA in 2024 essentially as a shell. Longevity programs completely abandoned.